Amgen, Inc. vs Gemini Space Station Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Gemini Space Station Inc trades at $4.02 (market cap $512.05M). The key difference: Amgen, Inc. is far larger — about 437.7× Gemini Space Station Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| AMGN | GEMI | |
|---|---|---|
Market Cap | $224.14B | $512.05M |
Sector | Health | Technology |
52-Week High | $417.20 | $32.52 |
52-Week Low | $271.18 | $3.90 |
Enterprise Value | $267.45B | $502.04M |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.
The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →